CDK2/TRKA Inhibitor PHA-848125 AC

An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types. (NCI Thesaurus)

YOU MAY ALSO LIKE

CDK2 wt Allele

Human CDK2 wild-type allele is located within 12q13 and is approximately 6 kb in length. This allele, which encodes cyclin-dependent kinase 2…

CDK2 Gene

This gene is involved in G2/M cell cycle regulation.

CDK16 wt Allele

Human CDK16 wild-type allele is located in the vicinity of Xp11.23 and is approximately 12 kb in length. This allele, which encodes…

CDK16 Gene

This gene is involved in cell cycle regulation and signal transduction.

CDK12 wt Allele

Human CDK12 wild-type allele is located in the vicinity of 17q12 and is approximately 73 kb in length. This allele, which encodes…

CDK12 Gene

This gene is involved in protein phosphorylation, RNA splicing and transcription elongation.